Global Search

Hide Filters

Showing 1086 results

Press release / Oct 27, 2021

Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma

Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory (r/r) follicular…
Story / Jan 06, 2015

Rebuilding blood

From Our Labs

Why are some sickle cell disease patients protected from the disease? Learn about our biomedical research in the field.
Press release / Feb 05, 2024

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or…
Press release / Jun 23, 2017

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved…
Press release / Mar 17, 2023

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months…
Press release / Dec 02, 2021

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Focused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to…
Press release / Aug 22, 2020

Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma

Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported…
Press release / Aug 04, 2020

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously…
Press release / Feb 19, 2016

Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…
Press release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 Study conclusions are drawn from the largest dataset and…

‹ Previous page
1
…
30
31
32
33
34
35
36
…
109
› Next page